Physicians Share Opinions on Electronic Health Records in Recent DoctorDirectory Survey

Asheville, NC May 16, 2013 -- DoctorDirectory, a leading marketing solutions company serving healthcare professionals and pharmaceutical industry clients, asked their community of HCPs to submit questions for a series of peer surveys. After collecting the submissions, the questions were divided up into separate surveys and sent to HCPs across the United States. Results from the EHR study were recently published.

EHR systems have plenty of room for improvement, according to physicians. When asked if EHR has improved productivity, 40% of physicians replied that it had not. Additionally, more than half of the physicians said that adoption of EHR has increased their overall workload. Adoption of EHR has not been overwhelmingly cost-effective either, as 50% of physicians say that adoption has not saved money.

Physicians were also interested in the features that accompany EHR adoption. 85% of responders said that they are currently ePrescribing as part of their EHR adoption. Further, two-thirds of physicians’ EHR systems are tablet and/or mobile friendly, allowing them to access the system across multiple devices.

More than 500 physicians responded to the survey; results are provided to DoctorDirectory’s HCP members via the DoctorDirectory.com healthcare professional website. For more information about this survey please visit ContactDD.com or call 828-255-0012 ext. 105.

About DoctorDirectory
DoctorDirectory specializes in providing healthcare professionals the opportunity to participate in market research and other programs that help shape the healthcare industry. DoctorDirectory's exclusive IncreaseRx marketing solution provides pharmaceutical brand teams with access to virtually all U.S. prescribers and generates measurable and verifiable incremental revenues in a gain-share arrangement. Visit ContactDD.com to learn more. Follow DoctorDirectory on Twitter @ContactDD

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.